Filtered By:
Countries: Norway Health

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 175 results found since Jan 2013.

Does coffee make you live longer?
Conclusion This study, conducted on a large number of people across Europe, was backed up by similar findings in the US. It appears to show some association between people who drink higher amounts of coffee and a reduced risk of death. But the "potentially beneficial clinical implications" need to be considered carefully for a number of reasons: Although the analyses were adjusted for some confounding variables, there may be a number of other factors that differ between the groups that account for the differences in death, such as socioeconomic status, family history, other medical conditions, and use of medic...
Source: NHS News Feed - July 12, 2017 Category: Consumer Health News Tags: Food/diet Source Type: news

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Publication date: Available online 3 August 2017 Source:The Lancet Diabetes & Endocrinology Author(s): Kåre I Birkeland, Marit E Jørgensen, Bendix Carstensen, Frederik Persson, Hanne L Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Thomas Nyström, Jan W Eriksson, Johan Bodegård, Anna Norhammar Background In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovas...
Source: The Lancet Diabetes and Endocrinology - August 4, 2017 Category: Endocrinology Source Type: research

Validation of intracranial hemorrhage in the Norwegian Patient  Registry
ConclusionCoding of ICH discharge diagnoses in the NPR is of high quality, showing that data from this registry can safely be used for medical research. Administrative and clinical health registries are established to monitor and manage healthcare services. Data from these registries can be used in epidemiological studies as they are easily obtained, include high number of patients, and provide both high external validity and statistical power. However, in order to be useful in research, health registries need to have accurate diagnoses and sufficient coverage in the population they serve. We validated coding of intracran...
Source: Brain and Behavior - January 23, 2018 Category: Neurology Authors: Lise R. Øie, Mattis A. Madsbu, Charalampis Giannadakis, Anders Vorhaug, Heidi Jensberg, Øyvind Salvesen, Sasha Gulati Tags: ORIGINAL RESEARCH Source Type: research

Thirty ‐day readmission after spontaneous intracerebral hemorrhage
ConclusionsAlmost one in five of our spontaneous ICH survivors was readmitted within 30 days, and most readmissions were caused by infections. Almost one in five of our spontaneous ICH survivors were readmitted within 30 days. Most readmissions were caused by infections.
Source: Brain and Behavior - January 1, 2018 Category: Neurology Authors: Anna Therese Bjerkreim, Andrej Netland Khanevski, Solveig Bergliot Glad, Lars Thomassen, Halvor Naess, Nicola Logallo Tags: ORIGINAL RESEARCH Source Type: research

Effects of introducing a fee for “inpatient overstays” on the rate of death and readmissions across municipalities in Norway
This study examines the effects of the reform on the rate of death and readmissions occurring within 60 days of hospitalization. We use aggregated municipal data for years 2009, 2010, 2012–2014 (N = 1646) for Norwegian patients (age 18+) hospitalized in the same years for COPD/asthma, heart failure, hip fracture, and stroke. We stratify our analyses of the municipal data by these patient groups. Our linear regression models test for moderated (interaction) effects whereby associations between the reform and the rate of death and readmissions vary by whether or not patients were classified as ready for discharge and in ...
Source: Social Science and Medicine - April 11, 2019 Category: Psychiatry & Psychology Source Type: research

Effects of introducing a fee for inpatient overstays on the rate of death and readmissions across municipalities in Norway
This study examines the effects of the reform on the rate of death and readmissions occurring within 60 days of hospitalization. We use aggregated municipal data for years 2009, 2010, 2012–2014 (N = 1646) for Norwegian patients (age 18+) hospitalized in the same years for COPD/asthma, heart failure, hip fracture, and stroke. We stratify our analyses of the municipal data by these patient groups. Our linear regression models test for moderated (interaction) effects whereby associations between the reform and the rate of death and readmissions vary by whether or not patients were classified as ready for discharge and in ...
Source: Social Science and Medicine - April 24, 2019 Category: Psychiatry & Psychology Source Type: research

Blood pressure in professional male football players in Norway
Conclusion: Although the prevalence of high BP in professional football players was low, our data indicate a novel association between elevated BP and reduced arterial compliance, increased left ventricle mass and left atrium volume even in young athletes. This emphasizes closer focus on BP measurements and standardized follow-up after preparticipation screening of athletes.
Source: Journal of Hypertension - March 9, 2013 Category: Cardiology Tags: ORIGINAL PAPERS: Epidemiology Source Type: research

Dapagliflozin Compared to DPP ‐4 inhibitors is Associated with Lower Risk of Cardiovascular Events and All‐cause Mortality in Type 2 Diabetes Patients (CVD‐REAL Nordic): a multinational observational study
ConclusionsDapagliflozin was associated with lower risks of cardiovascular events and all‐cause mortality compared to DPP‐4i in a in a real‐world clinical setting and broad T2D population.
Source: Diabetes, Obesity and Metabolism - August 1, 2017 Category: Endocrinology Authors: F Persson, T Nystr öm, M E Jørgensen, B Carstensen, H L Gulseth, M Thuresson, P Fenici, D Nathanson, J W Eriksson, A Norhammar, J Bodegard, K I Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Dapagliflozin is associated with lower risk of cardiovascular events and all ‐cause mortality in people with type 2 diabetes (CVD‐REAL Nordic) when compared with dipeptidyl peptidase‐4 inhibitor therapy: A multinational observational study
ConclusionsDapagliflozin was associated with lower risks of CV events and all‐cause mortality compared with DPP‐4 inhibitors in a real‐world clinical setting and a broad T2D population.
Source: Diabetes, Obesity and Metabolism - September 8, 2017 Category: Endocrinology Authors: Frederik Persson, Thomas Nystr öm, Marit E. Jørgensen, Bendix Carstensen, Hanne L. Gulseth, Marcus Thuresson, Peter Fenici, David Nathanson, Jan W. Eriksson, Anna Norhammar, Johan Bodegard, Kåre I. Birkeland Tags: ORIGINAL ARTICLE Source Type: research

Promoting evidence-based health care in Africa
Charles Shey Wiysonge, Director ofCochane  South Africa, gave an interview to the World Health Organization Bulletin. Here is a re-post , with premission, from their  recent publication.Charles Shey Wiysonge is devoted to encouraging better use of scientific evidence for health policies and programmes in African countries. He is the director of the South African Cochrane Centre, a unit of the South African Medical Research Council, and a professor of epidemiology and biostatistics at the department of Global Health in the Faculty of Medicine and Health Sciences at Stellenbosch University in South Africa. He was Chief Res...
Source: Cochrane News and Events - August 17, 2017 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Long-Term Exposure to Transportation Noise in Relation to Development of Obesity —a Cohort Study
Conclusion: Our results link transportation noise exposure to development of obesity and suggest that combined exposure from different sources may be particularly harmful. https://doi.org/10.1289/EHP1910 Received: 17 March 2017 Revised: 5 October 2017 Accepted: 9 October 2017 Published: 20 November 2017 Address correspondence to A. Pyko, Institute of Environmental Medicine, Karolinska Institutet, SE-171 77 Stockholm, Sweden. Telephone: 46(0) 852487561. Email: Andrei.pyko@ki.se Supplemental Material is available online (https://doi.org/10.1289/EHP1910). The authors declare they have no actual or potential competing fina...
Source: EHP Research - November 20, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research

Does a history of cardiovascular disease or cancer affect mortality after SARS-CoV-2 infection?
Abstract BACKGROUND: Cardiovascular disease and cancer have been described as possible risk factors for COVID-19 mortality. The purpose of this study was to investigate whether a history of cardiovascular disease or cancer affects the risk of dying after a COVID-19 diagnosis in Norway. MATERIAL AND METHOD: Data were compiled from the Norwegian Surveillance System for Communicable Diseases, the Norwegian Cardiovascular Disease Registry and the Cancer Registry of Norway. Univariable and multivariable regression models were used to calculate both relative and absolute risk. RESULTS: In the first half of 20...
Source: Tidsskrift for den Norske Laegeforening - February 2, 2021 Category: General Medicine Authors: Kvåle R, Bønaa KH, Forster R, Gravningen K, Júlíusson PB, Myklebust TÅ Tags: Tidsskr Nor Laegeforen Source Type: research

Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Diabetes Metab. 2023 Jan 3:101418. doi: 10.1016/j.diabet.2022.101418. Online ahead of print.ABSTRACTBACKGROUND: Continued expansion of indications for sodium-glucose cotransporter-2 inhibitors increases importance of evaluating cardiovascular and kidney efficacy and safety of empagliflozin in patients with type 2 diabetes compared to similar therapies.METHODS: The EMPRISE Europe and Asia study is a non-interventional cohort study using data from 2014-2019 in seven European (Denmark, Finland, Germany, Norway, Spain, Sweden, United Kingdom) and four Asian (Israel, Japan, South Korea, Taiwan) countries. Patients with type 2 d...
Source: Diabetes and Metabolism - January 7, 2023 Category: Endocrinology Authors: Avraham Karasik Stefanie Lanzinger Elise Chia-Hui Tan Daisuke Yabe Dae Jung Kim Wayne H-H Sheu Cheli Melzer-Cohen Reinhard W Holl Kyoung Hwa Ha Kamlesh Khunti Francesco Zaccardi Anuradhaa Subramanian Krishnarajah Nirantharakumar Thomas Nystr öm Leo Niska Source Type: research